Abeona Therapeutics (ABEO) logo

Abeona Therapeutics (ABEO) stock

Gene therapies , market cap $167M

$2.42
-1.22%

Why is ABEO down?

Down 39% on Nov 9, and still 42% under its Nov 6 close.

  • Its Nov 9 results: cash, cash equivalents and short-term investments were $134.9M, from $146.8M the quarter before. It fell 39% on Nov 9.

Sources: Price history, Nov 9, 2026; Company release, Nov 9, 2026

−3Long-term trend below a falling 200-day average, down over one year, down over two years

Tell me next time ABEO moves

Free account, no card. An optional alert when ABEO moves or its score changes.Pro, $1 for a first month. An optional alert when ABEO moves or its score changes.Pro, 7 days free with a card. An optional alert when ABEO moves or its score changes.

Or see it live, free until Tuesday morning. No account.Or see one stock in full, free. No account.
1 more reason, free with an account →See every reason on ABEO →2 more reasons why ABEO fell on Nov 9, from its filings, with the other side, the timeline, and its peers, for Pro members.
Quality Score
-5
Poor
In its industry
#189of 273
Checks firing
1of 14
Trending down
From 52-week high
-68.4%
under its best in a year

ABEO's Quality Score rose 1 point on Fri, Nov 20, to -5. More shares traded than usual.

Follow ABEO's trial news. Pro members can get an alert when Abeona Therapeutics files news, and see its trials, share raises, and its CEO's filings.

Get an alert when ABEO files news on its trialsSee it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Cash$135M, about 8 quarters (2 years) at the last year's spendingOn Sep 30

Key facts on ABEO

Key facts on ABEO
Holding it backMoves 12.2% a day with no profit behind it
Latest filingS-3, Nov 18 Registered shares for a later sale (S-3)

ABEO in the news

Mon Nov 9Abeona Therapeutics® Acquires Phase 3-Ready APT-1011, Now SEC filing 6:30 AM ET · GlobeNewswire and 2 more ABEO closed −39.1% that day.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

Cash$135M, about 8 quarters (2 years) at the last year's spendingOn Sep 30

ABEO catalysts

Coming up

After its last 4 reports it closed -14.3% on average, higher 1 of 4 times.

4 past catalysts since 2025, with sizes and sources, for Pro members.

What's next for ABEO, and how long its cash lasts

Cash runway Sep 30 balance sheet

About 8 quarters

$135M in cash and short-term investments, at its spending over the last year

What it means: how long the cash would last at the same pace, before any new money.

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

No shelf registration or at-the-market program on file in the last three years.

For Pro members: 2 raises and their amounts, and the share count against a year ago.

Insiders

Director Faith L. Charles bought 15,000 shares on Nov 13. 31 more insider trades this year.

From Form 4: open-market buys and sales only.

For Pro members: every trade, and Vishwas Seshadri’s 21 filings and quotes.

Get an alert when ABEO files news on its trialsA free account. No card.Pro: $1 first month.Pro, 7 days free with a card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

12 more FDA dates and 98 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 144 dates, ranked →See all 144 dates, ranked →Start Pro

How ABEO ranks in Biotech

ABEO is #189 of 273 by Quality Score.

How ABEO ranks in Biotech
RankStockQuality Score
189Abeona Therapeutics (ABEO) logoABEOAbeona Therapeutics-5

More in Biotech

When does ABEO report earnings, and what happens after?

Expected to report Tue Mar 16, before the open (in 115 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What ABEO reported on Nov 9, 2026

The quarter

Sales of $13.5M.

The quarter that ended Sep 30, from the company's press release

The press releaseThe filing on EDGAR

Where the sales came from

Where the quarter's sales came from
LineQ3
2026
Q2
2026
Q3
2025
By product
Product$13.5M100%$11.4M100%$0–

Each quarter's sales and their share of its total. Figures as filed (SEC filing, Nov 9)

1 more line, for Pro members.

The outlook

No outlook figures read from this release.

The numbers

Market value
$167M
today
Sales
$39M
last 12 months
Free cash flow
-$66.3M
last 12 months

3 more figures, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on ABEO: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

+0.5%-14.9%-39.1%
May 13Aug 13Nov 9
ReportedGapReaction5
days
Nov 9, 2026Before open-13.2%-39.1%-42.0%
Aug 13, 2026Before open-18.4%-14.9%-17.8%
May 13, 2026Before open+2.3%+0.5%-9.9%

ABEO closed higher after 1 of its last 4 reports.

All 4 reports, and ABEO's Quality Score going into each

ABEO sales and profit by year

Sales and profit by year

Sales grew in two of the last four years, to $3.5M in 2023. It turned a profit in 2025 after a loss in 2023.

ABEO has 1 of 14 chart checks firing

Volume1 of 3 shown
Tight range1 of 3 shown
Buying1 of 3 shown
The other 10 checks on ABEO, and all 14 on every stock.Get in free →See the top 3 →Start Pro

ABEO RSI on Nov 20: 26.7, below its 50-day and 200-day averages

Not scored

RSI 26.7, MACD below signal, below both averages. Not scored.

The deep dive on ABEO

8 more findings on ABEO, each with its source, for Pro members.

ABEO share count over time

7% more shares than a year earlier.

Weighted shares, quarter to Sep 30, 2026, both from one filing

Shares of ABEO outstanding, as filed
Shares
outstanding
As
of
57.1MNov 5, 2026
57.2MAug 10, 2026
57MMay 8, 2026
57MMar 11, 2026
Offerings, shelves, and splits of ABEO, from its filings
From its
filings
Filed
Registered shares for a later sale (S-3)Nov 18, 2026
Set up an at-the-market program for up to $75M of shares, about 45% of its market valueJun 21, 2024
Registered shares for a later sale (S-3)Jun 12, 2024
Priced a sale of sharesMay 3, 2024

ABEO insider trades

One insider bought $34K across 1 filing, and 7 insiders sold $1.7M across 18 filings, in the last 6 months. The newest:

BuyFaith L. Charles$34KDirectorat $2.29 on Nov 13, filed Nov 16

All 19 insider filings on ABEO from the last six months, for Pro members.

All ABEO insider trades

ABEO's officers and directors

Officers and directors with a Form 4 in the last 12 months.

6 more officers and directors file at ABEO.

See insider trades by person

Which ETFs hold ABEO?

In ETFs: ABEO is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Abeona Therapeutics

Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.

226 employeesCleveland, OHabeonatherapeutics.com

Here is what Pro members see.

  • The same page for Pro members, on Microsoft

    Its Quality Score and rank, the line that drives it, and the live price.

  • The full chart

    A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.

  • Every line of the score

    Price action, the company, and signals, each with its points, on ABEO and every other stock.

  • FDA dates, counted down

    Each date in the company's words, its cash against the date, and an optional alert before it.

  • CEOs buying their own stock

    Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.

  • Congress trades

    A member's trades, newest first, each with its amount. Sort and filter the whole list.

  • 14 chart checks, read for you

    The ones firing on the stock, each in plain words, its rule a tap away.

  • Earnings, week by week

    Who reports each day, and how each stock took its last four reports.

  • The market map

    Every stock a box, colored by its Quality Score.

  • Themes, ranked live

    Each theme's stocks ranked by Quality Score, live. Here, AI chips.

  • The top 10, every day

    The ten highest Quality Scores at each close, kept day by day, week by week.

  • Optional alerts, your way

    Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.

  • Your watchlist, scored

    Your stocks by Quality Score, today's move, or name.

  • On your phone and your laptop

    The same account and watchlist on both, each laid out for its screen.

  • Prices refresh every 2.5 seconds during market hours.
  • Optional alerts by push, email, or the bell.
  • Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

  • What would turn ABEO's score around: 8 things
  • 7 more filings explained, a plain line each
  • 4 more things pulling ABEO's score down
BreakawayNov 16Faith L. Charles bought ABEO$34K at $2.29, filed Nov 16

Alerts are optional.

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

Straight AnswersStraight Answers

As of Nov 21, 2026: ABEO's Quality Score is -5 (Poor), #189 of 273 in Biotech. Insiders bought $34K and sold $1.7M in the last 6 months (Form 4).

What does ABEO's Quality Score say?

ABEO scores -5 today, which Breakaway calls Poor. It is #189 of 273 in Biotech by Quality Score, with 1 of 14 chart checks firing. Down 39% on Nov 9, and still 42% under its Nov 6 close. Cash lasts about 8 quarters at its spending (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is ABEO's Quality Score?

ABEO scores -5 today, which Breakaway calls Poor (below zero). That is #189 of 273 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind ABEO's -5.

Are insiders buying ABEO?

One insider bought $34K across 1 filing, and 7 insiders sold $1.7M across 18 filings, in the last 6 months. The newest is Faith L. Charles, Director, who bought $34K on Nov 13. Every filing, with the scored weight, for Pro members.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Only on the public pages, which run at least 15 minutes behind. Pro members see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included. The one stock you open in full is live too.

Every US stock, ranked live.

Insider and Congress trades, the chart, and the financials, in one score.

See all 3,170 stocks rankedSee all 3,170 stocks rankedStart Pro

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

What's next for Abeona Therapeutics: from its SEC filings and ClinicalTrials.gov, the company's words, the registry's dates, and arithmetic, not a forecast. Companies often miss the dates they set.

The moves after past earnings reports are past behavior, not a forecast.

The price, the score, the chart checks and readings, and the industry rank on this page are delayed at least 15 minutes.

Our top-scored stocks' record: Oct 2021 to Sep 2026, before costs. Recorded live since Sep 9, 2026.

Breakaway publishes impersonal securities research and analytical tools: one formula, the same score for everyone. It is not personalized investment advice, and nothing here is a recommendation to buy or sell any security.

Market data from a licensed vendor. The age of every quote is shown on the page.

This browser is too old to show this page right. Update it, or open this page in Safari or Chrome.